Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Safety of prophylactic intracameral cefuroxime (Aprokam®) ophthalmic solution in cataract surgery patients

Poster Details

First Author: O.Arslan TURKEY

Co Author(s):    C. Dogan   M. Onal   M. Mangan   I. Toker           

Abstract Details

Purpose:

To determine the safety of prophylactic intracameral cefuroxime (Aprokam®) after cataract surgery in patients.

Setting:

Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

Methods:

In this retrospective study of consecutive patients who had phacoemulsification cataract surgery, were treated with intracameral cefuroxime ophthalmic solution (Aprokam®). Each Aprokam® vial contains 50 mg of cefuroxime powder, which is reconstituted with 5 mL of sterile sodium chloride 0.9 % solution for injection; 0.1 mL of the reconstituted solution (i.e. 1 mg of cefuroxime) is then administered to the patient by intra- cameral injection The main outcome measures were anterior chamber reaction, best corrected visual acuity (BCVA), corneal endothelial cell count (ECC), and central corneal thickness (CCT).

Results:

Fourtyfive patients were recruited. The mean age was 62.16±4.93y. All eyes had improved postoperative BCVA. The mean BCVA was 0.15 preoperatively and 0.85 postoperatively. All eyes had no anterior chamber cells at the first day after surgery and subsequent follow up examinations. The mean ECC was 2548.20 cells/mm2 preoperatively and 2405.65 cells/mm2 1mo postoperatively.

Conclusions:

No untoward effects were observed after intracameral injection of cefuroxime ophthalmic solution (Aprokam®) in terms of anterior chamber reaction, CCT, ECC, and visual rehabilitation at the conclusion of cataract surgery in patients.

Financial Disclosure:

NONE

Back to Poster listing